Scientific Sessions 2024  /  Bridging Cerebral Circuits: Innovations in Stroke and Cognitive Outcomes  /  Elevated International Normalized Ratio Is Inconsistently Associated With Ischemic Stroke Severity and Outcomes for Patients Taking Direct Oral Anticoagulants
Logo

American Heart Association

  337
  0

Final ID: Su4047

Elevated International Normalized Ratio Is Inconsistently Associated With Ischemic Stroke Severity and Outcomes for Patients Taking Direct Oral Anticoagulants

Abstract Body (Do not enter title and authors here): Introduction/Background: Higher International Normalized Ratio (INR), a measure of the extrinsic common and final pathways of the coagulation cascade, has been associated with improved ischemic stroke outcomes for patients taking Warfarin. However, the association between INR and ischemic stroke outcomes for patients taking direct oral anticoagulant drugs (DOACs) is not well understood.
Research Questions/Hypothesis: To determine whether INR is associated with ischemic stroke severity and outcomes for patients on preceding DOAC therapy.
Methods/Approach: We conducted a retrospective, observational cohort study that included consecutive patients with acute ischemic stroke and recent exposure to apixaban or rivaroxaban, presenting to hospitals participating in a nationwide quality improvement registry. We modeled the primary exposure, INR, as a continuous variable with restricted cubic splines. The primary endpoint was stroke severity on presentation, measured by the National Institutes of Health Stroke Scale (NIHSS). Secondary endpoints included in-hospital mortality, composite of in-hospital mortality and discharge to hospice, and modified Rankin Scale (mRS) at discharge. We adjusted for key confounding factors of age, sex, race/ethnicity, insurance status, and medical history, using the generalized estimating equations method to account for within-hospital clustering of patients.
Results/Data: In total, 54,527 patients were included of whom 32,883 patients were exposed to apixaban and 21,644 were exposed to rivaroxaban. Associations between INR and outcomes are shown in Table 1. For patients taking apixaban, INR was associated with NIHSS >=16 at presentation (OR 1.18 [95% CI 1.10-1.27, p<.001] per 0.1 up to 1.1 and OR 1.03 [95% CI 1.02-1.04, p<.001] per 0.1 above 1.1). For patients taking rivaroxaban, INR up to 1.1 was associated with NIHSS >=16 at presentation (OR 1.10 [95% CI 1.02-1.20, p=0.02]) but INR greater than 1.1 was inversely associated with NIHSS >=16 at presentation (OR 0.97 [95% CI 0.96-0.98, p<.001]).
Conclusions: Associations between INR and stroke severity and outcomes differ across DOACs and are not consistent with prior results seen for patients taking warfarin.
  • Lusk, Jay  ( Duke University , Durham , North Carolina , United States )
  • Sun, Jie-lena  ( Duke Clinical Research Institute , Durham , North Carolina , United States )
  • Mac Grory, Brian  ( Duke Clinical Research Institute , Durham , North Carolina , United States )
  • Schwamm, Lee  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Smith, Eric  ( UNIVERSITY OF CALGARY , Calgary , Alberta , Canada )
  • Fonarow, Gregg  ( UCLA MEDICAL CENTER , Los Angeles , California , United States )
  • Bhatt, Deepak  ( Mount Sinai , New York , New York , United States )
  • Saver, Jeffrey  ( GEFFEN SCHOOL OF MEDICINE AT UCLA , Los Angeles , California , United States )
  • Reeves, Mathew  ( MICHIGAN STATE UNIVERSITY , East Lansi , Michigan , United States )
  • Matsouaka, Roland  ( Duke University , Durham , North Carolina , United States )
  • Xian, Ying  ( UTSW , Dallas , Texas , United States )
    • Author Disclosures:
    Jay Lusk: DO NOT have relevant financial relationships | Roland Matsouaka: DO NOT have relevant financial relationships | Ying Xian: DO NOT have relevant financial relationships | Jie-Lena Sun: DO NOT have relevant financial relationships | Brian Mac Grory: No Answer | Lee Schwamm: DO have relevant financial relationships ; Consultant:genentech:Active (exists now) ; Consultant:penumbra:Past (completed) ; Consultant:medtronic:Active (exists now) | Eric Smith: No Answer | Gregg Fonarow: DO have relevant financial relationships ; Consultant:Abbott:Past (completed) ; Consultant:Johnson and Johnson:Past (completed) ; Consultant:Pfizer:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Eli Lilly:Past (completed) ; Consultant:Boehringer Ingelheim:Past (completed) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Astra Zeneca:Past (completed) ; Consultant:Amgen:Past (completed) | Deepak Bhatt: DO have relevant financial relationships ; Advisor:Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys:Active (exists now) ; Other (please indicate in the box next to the company name):Trustee: American College of Cardiology; Unfunded Research: FlowCo:Active (exists now) ; Other (please indicate in the box next to the company name):Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions;:Active (exists now) ; Royalties/Patent Beneficiary:Royalties: Elsevier (Editor, Braunwald’s Heart Disease):Active (exists now) ; Researcher:Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio;:Active (exists now) ; Royalties/Patent Beneficiary:Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria: Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee);:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum):Active (exists now) ; Other (please indicate in the box next to the company name):Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);:Active (exists now) ; Consultant:Broadview Ventures, GlaxoSmithKline, Hims, SFJ, Youngene:Active (exists now) ; Other (please indicate in the box next to the company name):Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock);:Active (exists now) | Jeffrey Saver: DO have relevant financial relationships ; Consultant:Medtronic:Active (exists now) ; Consultant:Astrocyte Pharma:Active (exists now) | Mathew Reeves: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Bridging Cerebral Circuits: Innovations in Stroke and Cognitive Outcomes

Sunday, 11/17/2024 , 11:30AM - 12:30PM

Abstract Poster Session

More abstracts on this topic:
A Contemporary Machine Learning-Based Risk Stratification for Mortality and Hospitalization in Heart Failure with Preserved Ejection Fraction Using Multimodal Real-World Data

Fudim Marat, Weerts Jerremy, Patel Manesh, Balu Suresh, Hintze Bradley, Torres Francisco, Micsinai Balan Mariann, Rigolli Marzia, Kessler Paul, Touzot Maxime, Lund Lars, Van Empel Vanessa, Pradhan Aruna, Butler Javed, Zehnder Tobias, Sauty Benoit, Esposito Christian, Balazard Félix, Mayer Imke, Hallal Mohammad, Loiseau Nicolas

Impact of Low Body Weight on Long-term Outcomes in Patients with Venous Thromboembolism: Insights from the COMMAND VTE Registry-2

Kobayashi Soichiro, Kim Kitae, Inoko Moriaki, Takase Toru, Tsuji Shuhei, Oi Maki, Takada Takuma, Otsui Kazunori, Sakamoto Jiro, Nishikawa Ryusuke, Sato Toru, Ogihara Yoshito, Dohi Kaoru, Yamashita Yugo, Kaneda Kazuhisa, Chatani Ryuki, Nishimoto Yuji, Ikeda Nobutaka, Kobayashi Yohei, Ikeda Satoshi

More abstracts from these authors:
Elevated International Normalized Ratio Is Associated with Severity of Intracerebral Hemorrhage for Patients Taking Direct Oral Anticoagulants

Lusk Jay, Matsouaka Roland, Xian Ying, Sun Jie-lena, Mac Grory Brian, Schwamm Lee, Smith Eric, Fonarow Gregg, Bhatt Deepak, Saver Jeffrey, Reeves Mathew

Race-Ethnic Specific Hospital Arrival Time of Acute Ischemic Stroke by State in the U.S.

Chen Bing Yu, Xian Ying, Uchino Ken, Man Shumei, Sun Jie-lena, Fonarow Gregg, Alhanti Brooke, Mac Grory Brian, Smith Eric, Schwamm Lee, Bhatt Deepak, Saver Jeffrey

4145909_File000000.jpg
4145909_File000000.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available